Yahya Shaikh, Ishaan Gupta, Sophia Purekal, Mary Jane E Vaeth, Maisha Foyez, Charles D Callahan, Maryam Elhabashy, Minahil Cheema, Resham Rahat, James R Ficke, Albert W Wu, Paul G Auwaerter, Melinda E Kantsiper, Zishan K Siddiqui
{"title":"Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19: Lessons for Future Pandemics.","authors":"Yahya Shaikh, Ishaan Gupta, Sophia Purekal, Mary Jane E Vaeth, Maisha Foyez, Charles D Callahan, Maryam Elhabashy, Minahil Cheema, Resham Rahat, James R Ficke, Albert W Wu, Paul G Auwaerter, Melinda E Kantsiper, Zishan K Siddiqui","doi":"10.1007/s11606-025-09386-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and methods: </strong>We conducted a single-center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021, and May 14, 2021.</p><p><strong>Results: </strong>Among the 2406 eligible participants, mAb treatment was significantly underutilized among African American patients compared to White patients (OR 1.8; 95% CI 1.5-2.1). The higher proportion of refusals and cancellations of mAb treatment may suggest a higher level of hesitancy among African American patients (OR 1.7; 95% CI 1.3-2.1).</p><p><strong>Conclusion: </strong>Evaluating the reasons and addressing racial disparities in hesitancy of novel therapeutics under Emergency Use Authorization (EUA) offer a critical opportunity to address the inequities in pandemic care.</p>","PeriodicalId":15860,"journal":{"name":"Journal of General Internal Medicine","volume":" ","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of General Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11606-025-09386-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background and methods: We conducted a single-center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021, and May 14, 2021.
Results: Among the 2406 eligible participants, mAb treatment was significantly underutilized among African American patients compared to White patients (OR 1.8; 95% CI 1.5-2.1). The higher proportion of refusals and cancellations of mAb treatment may suggest a higher level of hesitancy among African American patients (OR 1.7; 95% CI 1.3-2.1).
Conclusion: Evaluating the reasons and addressing racial disparities in hesitancy of novel therapeutics under Emergency Use Authorization (EUA) offer a critical opportunity to address the inequities in pandemic care.
期刊介绍：
The Journal of General Internal Medicine is the official journal of the Society of General Internal Medicine. It promotes improved patient care, research, and education in primary care, general internal medicine, and hospital medicine. Its articles focus on topics such as clinical medicine, epidemiology, prevention, health care delivery, curriculum development, and numerous other non-traditional themes, in addition to classic clinical research on problems in internal medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
